Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$5.43
+1.3%
$4.80
$2.78
$6.45
$435.51M0.3385,310 shs209,892 shs
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$1.05
$0.96
$0.84
$2.38
$470.84M0.813.76 million shs5.40 million shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$7.65
+2.0%
$6.87
$1.85
$8.45
$114.62M0.08107,558 shs34,795 shs
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$11.29
-0.5%
$10.53
$5.65
$13.25
$395.80M1.09188,559 shs210,738 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+6.05%+14.32%+22.85%+55.14%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.00%+2.94%+16.01%+0.96%-13.22%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%-1.80%+9.44%+30.32%+135.38%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
0.00%-3.67%+11.23%+13.70%+39.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$5.43
+1.3%
$4.80
$2.78
$6.45
$435.51M0.3385,310 shs209,892 shs
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$1.05
$0.96
$0.84
$2.38
$470.84M0.813.76 million shs5.40 million shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$7.65
+2.0%
$6.87
$1.85
$8.45
$114.62M0.08107,558 shs34,795 shs
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$11.29
-0.5%
$10.53
$5.65
$13.25
$395.80M1.09188,559 shs210,738 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+6.05%+14.32%+22.85%+55.14%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.00%+2.94%+16.01%+0.96%-13.22%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%-1.80%+9.44%+30.32%+135.38%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
0.00%-3.67%+11.23%+13.70%+39.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$7.0028.91% Upside
Canopy Growth Corporation stock logo
CGC
Canopy Growth
2.20
HoldN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
1.00
SellN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
2.50
Moderate Buy$17.0050.58% Upside

Current Analyst Ratings Breakdown

Latest CPIX, CGC, AVIR, and FENC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Boost Price TargetEqual Weight$6.00 ➝ $7.00
8/12/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
DowngradeSell (D-)Sell (E+)
8/12/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Reiterated RatingBuy$16.00 ➝ $18.00
8/12/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Boost Price TargetOutperform$13.00 ➝ $16.00
7/29/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
UpgradeSell (E+)Sell (D-)
7/17/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Reiterated RatingSell (D-)
7/17/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Reiterated RatingSell (D-)
7/14/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
DowngradeSell (D-)Sell (E+)
6/29/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
UpgradeSell (E+)Sell (D-)
6/24/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
Reiterated RatingSell (D-)
6/15/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
DowngradeSell (D-)Sell (E+)
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$2.55 per shareN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$251.01M1.88N/AN/A$1.11 per share0.95
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$44.52M2.57$0.37 per share20.86$1.14 per share6.71
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$44.64M8.87N/AN/A$1.21 per share9.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$2.08N/AN/AN/AN/A-64.25%-57.12%11/11/2026 (Estimated)
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$190.29M-$0.45N/AN/AN/A-65.33%-21.91%-14.34%11/6/2026 (Estimated)
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$2.84M-$0.71N/AN/AN/A-34.40%-28.81%-9.25%11/3/2026 (Estimated)
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$9.74M-$0.13N/A11.52N/A-6.09%-5.71%-2.37%N/A

Latest CPIX, CGC, AVIR, and FENC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.5550-$0.41+$0.1450-$0.41$33.03 millionN/A
8/11/2026Q2 2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$0.02$0.05+$0.03$0.05$16.21 million$17.87 million
8/7/2026Q1 2027
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.04-$0.02+$0.02-$0.02$58.21 million$142.62 million
8/4/2026Q2 2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$0.13-$0.20-$0.07-$0.29$8.50 million$0.17 million
6/15/2026Q4 2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.06-$0.17-$0.11-$0.05$53.43 million$51.22 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/AN/AN/AN/AN/A

Latest CPIX, CGC, AVIR, and FENC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/13/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$1.507/23/20267/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.13
8.13
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.31
3.04
2.39
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A
0.96
0.96
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/A
5.85
5.66

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3.33%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
55.51%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.35%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
42.07%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
10.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7080.21 million62.88 millionOptionable
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1,128448.42 million446.85 millionOptionable
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.98 million8.68 millionOptionable
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
1035.06 million31.30 millionOptionable

Recent News About These Companies

Adherex Technologies Q2 Earnings Call Highlights
Fennec Announces Results of Annual Meeting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$5.43 +0.07 (+1.31%)
As of 08/21/2026 04:00 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$1.05 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.65 +0.15 (+2.00%)
As of 08/21/2026 04:00 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Adherex Technologies stock logo

Adherex Technologies NASDAQ:FENC

$11.29 -0.06 (-0.53%)
As of 08/21/2026 04:00 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.